Zobrazeno 1 - 10
of 370
pro vyhledávání: '"TATEAKI NAITO"'
Autor:
Kosei Doshita, Tateaki Naito, Suguru Matsuda, Meiko Morita, Motoki Sekikawa, Keita Miura, Hiroaki Kodama, Michitoshi Yabe, Noboru Morikawa, Yuko Iida, Nobuaki Mamesaya, Haruki Kobayashi, Ryo Ko, Kazushige Wakuda, Akira Ono, Haruyasu Murakami, Hirotsugu Kenmotsu, Toshiaki Takahashi
Publikováno v:
Thoracic Cancer, Vol 15, Iss 25, Pp 1831-1841 (2024)
Abstract Background Chemotherapy‐induced anorexia is a common occurrence in patients undergoing treatment for advanced lung cancer. However, the relationship between chemotherapy‐induced anorexia and weight loss during platinum‐based chemothera
Externí odkaz:
https://doaj.org/article/1c619e4840f7419cb18ab6e638421ba1
Autor:
Hiroaki Kodama, Haruyasu Murakami, Nobuaki Mamesaya, Haruki Kobayashi, Shota Omori, Kazushige Wakuda, Ryo Ko, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Shingo Matsumoto, Koichi Goto, Tetsuo Shimizu, Yasuhiro Gon, Toshiaki Takahashi
Publikováno v:
Thoracic Cancer, Vol 15, Iss 21, Pp 1665-1672 (2024)
Abstract Background The AmoyDx Pan lung cancer PCR panel (AmoyDx PLC panel) has been approved as a companion diagnostic tool for multiple anticancer agents in patients with non‐small cell lung cancer (NSCLC). However, the suitability of cytology sp
Externí odkaz:
https://doaj.org/article/6c1fe2baa59945ae9b7a90da2d5d7001
Autor:
Yuko Iida, Kazushige Wakuda, Hirotsugu Kenmotsu, Kosei Doshita, Hiroaki Kodama, Naoya Nishioka, Eriko Miyawaki, Taichi Miyawaki, Nobuaki Mamesaya, Haruki Kobayashi, Shota Omori, Ryo Ko, Akira Ono, Tateaki Naito, Haruyasu Murakami, Takashi Sugino, Yasuhiro Gon, Toshiaki Takahashi
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract The efficacy of second-line chemotherapy in patients with pulmonary large cell neuroendocrine carcinoma (LCNEC) is unclear. This study aimed to evaluate the efficacy of second-line chemotherapy in patients with pulmonary LCNEC. We retrospect
Externí odkaz:
https://doaj.org/article/9ca57d0b679e413492866893556df8e6
Autor:
Haruki Kobayashi, Tateaki Naito
Publikováno v:
Thoracic Cancer, Vol 15, Iss 34, Pp 2456-2457 (2024)
Externí odkaz:
https://doaj.org/article/90ad7cfd9e6b4286ba6fb63c7ff572cb
Autor:
Meiko Morita, Akira Ono, Motoki Sekikawa, Kosei Doshita, Keita Miura, Hiroaki Kodama, Michitoshi Yabe, Noboru Morikawa, Yuko Iida, Nobuaki Mamesaya, Haruki Kobayashi, Ryo Ko, Kazushige Wakuda, Hirotsugu Kenmotsu, Tateaki Naito, Haruyasu Murakami, Mitsuhiro Isaka, Yasuhisa Ohde, Toshiaki Takahashi
Publikováno v:
Cancer Reports, Vol 7, Iss 9, Pp n/a-n/a (2024)
ABSTRACT Background Mutations in the epidermal growth factor receptor (EGFR) gene are the most common targetable gene alterations in non‐small cell lung cancer (NSCLC). In Japan, approximately 40% of patients who undergo surgical resection for non
Externí odkaz:
https://doaj.org/article/3c7205c59c0848928a7fc40d19564462
Autor:
Yuko Iida, Kazushige Wakuda, Takuya Kawata, Meiko Morita, Motoki Sekikawa, Kosei Doshita, Michitoshi Yabe, Hiroaki Kodama, Keita Miura, Noboru Morikawa, Nobuaki Mamesaya, Haruki Kobayashi, Ryo Ko, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Haruyasu Murakami, Yasuhiro Gon, Toshiaki Takahashi
Publikováno v:
Thoracic Cancer, Vol 15, Iss 6, Pp 477-485 (2024)
Abstract Background Which patients benefit from the addition of immune checkpoint inhibitors (ICIs) to chemotherapy for small cell lung cancer (SCLC) remains unclear. There have been few reports on the efficacy of ICIs based on conventional immunohis
Externí odkaz:
https://doaj.org/article/e463e71dc180423c8cb17938224f6040
Autor:
Tateaki Naito, Hidetaka Wakabayashi, Sakiko Aso, Masaaki Konishi, Masakazu Saitoh, Vickie E. Baracos, Andrew J. Coats, Stefan D. Anker, Lawrence Sherman, Tatiana Klompenhouwer, Noriyasu Shirotani, Akio Inui, Hidenori Arai
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 15, Iss 1, Pp 387-400 (2024)
Abstract Background Cancer cachexia is a severe complication of advanced malignancy, with few therapeutic options. To promote interprofessional care for cancer cachexia, healthcare providers' needs should be addressed in detail. This pre‐planned su
Externí odkaz:
https://doaj.org/article/d38b8bba514f4e35a90e59dfdf3c9938
Autor:
Motoki Sekikawa, Haruyasu Murakami, Meiko Morita, Kosei Doshita, Keita Miura, Hiroaki Kodama, Noboru Morikawa, Yuko Iida, Nobuaki Mamesaya, Haruki Kobayashi, Ryo Ko, Kazushige Wakuda, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Hirofumi Chiba, Toshiaki Takahashi
Publikováno v:
Thoracic Cancer, Vol 14, Iss 35, Pp 3475-3482 (2023)
Abstract Background Amrubicin (AMR) regimens have shown efficacy as second‐line treatment in patients with small cell lung cancer (SCLC); however, adverse events such as febrile neutropenia (FN) sometimes preclude their use. Further, the safety and
Externí odkaz:
https://doaj.org/article/4fa201b940bf4f3497e40475cb88b5de
Autor:
Hidenori Arai, Keisuke Maeda, Hidetaka Wakabayashi, Tateaki Naito, Masaaki Konishi, Prasert Assantachai, Wai Tung Auyeung, Chalobol Chalermsri, Wei Chen, Justin Chew, Ming‐Yueh Chou, Chih‐Cheng Hsu, Allyn Hum, In Gyu Hwang, Toshimi Kaido, Lin Kang, Shahrul Bahyah Kamaruzzaman, Miji Kim, Jenny Shun Wah Lee, Wei‐Ju Lee, Chih‐Kuang Liang, Wee Shiong Lim, Jae‐Young Lim, Yen Peng Lim, Raymond See‐Kit Lo, Terence Ong, Wen‐Harn Pan, Li‐Ning Peng, Pornpoj Pramyothin, Nurul Huda Razalli, Masakazu Saitoh, Suzana Shahar, Han Ping Shi, Heng‐Hsin Tung, Yasuhito Uezono, Stephan vonHaehling, Chang Won Won, Jean Woo, Liang‐Kung Chen
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 14, Iss 5, Pp 1949-1958 (2023)
Abstract Chronic diseases often lead to metabolic disorders, causing anabolic resistance and increased energy consumption, which result in cachexia. Cachexia, in turn, can lead to major clinical consequences such as impaired quality of life, shortene
Externí odkaz:
https://doaj.org/article/53bd981485d042568bd1471bb4f7009e
Autor:
Yuichiro Nishibori, Hirotsugu Kenmotsu, Kenju Ando, Ayumi Tonsho, Suguru Matsuda, Meiko Morita, Motoki Sekikawa, Kosei Doshita, Noboru Morikawa, Keita Miura, Hiroaki Kodama, Michitoshi Yabe, Yuko Iida, Nobuaki Mamesaya, Haruki Kobayashi, Ryo Ko, Kazushige Wakuda, Akira Ono, Tateaki Naito, Haruyasu Murakami, Hideyuki Harada, Toshiaki Takahashi
Publikováno v:
Cancer Treatment and Research Communications, Vol 41, Iss , Pp 100849- (2024)
Objectives: The current standard treatment for locally advanced non-small cell lung cancer (LA-NSCLC) is concurrent chemoradiation therapy (CCRT) followed by durvalumab consolidation therapy. Although the trial revealed the survival benefit of adding
Externí odkaz:
https://doaj.org/article/10a0f9b6834e4795925cd6a167840c00